1112P Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition.

Autor:	Ziogas, D.C.1 (AUTHOR), Lyrarakis, G.1 (AUTHOR), Liontos, M.2 (AUTHOR), Anastasopoulou, A.1 (AUTHOR), Bouros, S.1 (AUTHOR), Gkoufa, A.1 (AUTHOR), Diamantopoulos, P.1 (AUTHOR), Gogas, H.3 (AUTHOR)
Zdroj:	Annals of Oncology. 2024 Supplement 2, Vol. 35, pS735-S736. 2p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu